Background: Interleukin (IL)-33 is implicated in the pathophysiology of asthma and
new drugs to treat asthma that complement or overcome the shortcoming of those that are currently available.
Cytokines produced by epithelial cells and other cell types at the barrier surface, including thymic stromal lymphopoietin (TSLP), IL-25, and IL-33, play an important role in regulating type 2 immunity. 5 Among these cytokines, IL-33 is unique in that it is constitutively expressed and stored in the nucleus of tissue cells. 6 Nuclear localization is likely critical for IL-33 regulation because a lack of the nuclear localization domain causes extracellular leakage of the cytokine and subsequent lethal eosinophilic and neutrophilic inflammation of various organs. 7 Abundant in vitro and in vivo evidence now supports roles for IL-33 in innate and adaptive type-2 immune responses. 8 Evidence suggesting roles for IL-33 in human asthma and allergic diseases has been forthcoming. 9, 10 Despite these advances in the field, the mechanisms responsible for production and release of IL-33 are still poorly understood.
Oxidative stress is involved in various biological and pathologic processes. 11 The potential roles for oxidative stress in asthma and allergies have been studied. 12 However, the results from therapeutic studies of these diseases with exogenous antioxidant agents have been inconclusive. 13 A detailed mechanistic understanding of how oxidative stress is involved in the development and/or exacerbation of allergic airway inflammation is still lacking.
Recent studies show that a key element in the regulation of oxidative stress is the transcription factor nuclear factor-erythroid-2-related factor 2 (Nrf2). 14, 15 Under physiologic conditions, Nrf2 is localized and suppressed in the cytoplasm by binding to Kelch-like ECH-associated protein 1 (Keap1). Upon exposure to oxidative stress, Nrf2 translocates to the nucleus and initiates transcription of more than 200
antioxidant and cytoprotective genes. 16 Because the Nrf2 pathway would provide broad control over oxidative stress responses by activating a number of antioxidant molecules, it could be a therapeutic target for a variety of diseases such as neurodegenerative disorders, diabetes complications, and cardiovascular diseases. 17, 18 The Nrf2 pathway may be particularly relevant to the lungs because the organ is exposed to a variety of oxidative insults from our atmospheric environment, including tobacco smoke, air pollution, and allergens. Indeed, asthma is generally characterized by a loss of antioxidant activities. 12 Thus, the goals of this project were to investigate the role of oxidative stress in controlling IL-33 release in airway epithelium and to examine the efficacy of Nrf2-activators for protecting hosts from type-2 immune responses and airway inflammation.
| MATERIALS AND METHODS

| Mice and reagents
BALB/cJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Seven-to nine-week-old female mice were used in this study. epithelial (hBE) cells were exposed to 100 lg/mL Alternaria extract for 15 minutes, and production of intracellular ROS was examined by a cytoplasm-localizing ROS probe (CellROX â Orange). As compared to hBE cells exposed to medium alone, significant increases in cytoplasmic fluorescence was detected in Alternaria-exposed hBE cells, consistent with an increase in ROS production within this compartment ( Figure 1A ,B). Similar findings were observed with nuclearlocalizing probes (CellROX â Green) ( Figure 1A ,B). Kinetic studies showed that an increase in cytoplasmic ROS was observed as early as 5 minutes after cellular exposure to Alternaria extract, and that the level continued to increase at least for 20 minutes (Fig. S1 ). Pretreatment with the ROS scavenger GSH (5 mmol L
À1
) abolished the increase in Alternaria-induced ROS production ( Figure 1A ,B). Altogether, these findings suggest that GSH-sensitive ROS are quickly produced within the cytoplasm and nucleus of hBE cells when they are exposed to Alternaria extract. In addition, pretreatment of hBE cells with DPI, which inhibits mitochondrial ROS production, 26 also inhibited ATP release with an IC 50
Reactive oxygen species scavengers were also effective in preventing the prolonged increase in [Ca 2+ ] i after Alternaria exposure.
As shown in Figure 2A Figure 3B ) as in native hBE cells. 6, 22 When hBE33 cells were exposed to Alternaria extract, IL-33 was released into cell-free supernatant as early as 30 minutes after exposure ( Figure 3C ). Western blot analysis showed that processed 19-kDa IL-33 was released into the extracellular media, while full-length 31-kDa IL-33 was retained within the cells ( Figure 3D ). Importantly, Figure 3G ). GSH did not affect production of RANTES by hBE cells that were exposed to 100 lg/mL Alternaria extract (Fig. S2) , suggesting that it is unlikely that GSH causes nonspecific inhibitory effects on hBE cells.
| Oxidative stress is involved in Alternariainduced IL-33 release in vivo
To investigate the role of oxidative stress in IL-33 release in vivo,
we used a mouse model. When na€ ıve mice were exposed to Alternaria extract, BAL IL-33 levels increased within 1 hour and declined thereafter, while lung levels of IL-33 reached a peak 6 hours after exposure ( Figure 4A ). After 1 hour, processed 19-kDa IL-33 was detected in BAL fluids, while the full-length 31-kDa IL-33 remained in the lung tissues ( Figure 4B ), which was similar to the observations from the hBE33 in vitro model ( Figure 3D ). Importantly, administration of the ROS scavengers GSH and NAC to the airways abolished Alternaria-induced IL-33 secretion and type-2 cytokine production ( Figure 4C,D) . However, GSH did not affect IL-33-driven type-2 cytokine production ( Figure 4D ). Thus, oxidative stress plays a key role in allergen-induced IL-33 secretion in airway epithelium both in vitro and in vivo. Figure 5A,B, Fig. S3A) . Similarly, the ATP secretion evoked daily for 18 days, which is equivalent to roughly 12.5 mg CDDO-Me per dose in humans. 31 As a reference, human noncancer clinical trials have used a daily oral dose of 20-150 mg CDDO-Me. 32 The genes with expression in CDDO-Me-treated mice that were more than doubled compared to DMSO-treated control mice included glutamate-cysteine ligase catalytic (Gclc), glutathione S-transferase pi 1 (Gstp1), NADPH:quionone oxidoreductase (Nqo1), thioredoxin 1 (Txnrd1), aldehyde oxidase 1 (Aox1), sulfiredoxin 1 (Srxn1), and heat shock protein family member 1A (Hspa1a) (Fig. S4 ). These are all previously reported Nrf2 target genes. 28 To examine whether CDDO-Me modulates GSH levels in the lungs, we treated mice with 100 lg CDDO-Me ip. daily for 3 days and then exposed them to 50 lg Alternaria extract (Fig. S5A ). As expected, GSH was constitutively detected in both BAL fluids and lung tissue in control mice treated with DMSO. CDDO-Me treatment further elevated the levels of GSH in BAL fluids and lungs by 98% and 40%, respectively (Fig. S5B) . When CDDO-Me-treated mice were exposed to Alternaria extract, significant reductions were observed in IL-33 released into airway lumens (P<.05).
| Nrf2 activation inhibits allergic airway inflammation
Given the inhibitory effects of CDDO-Me on IL-33 release, we investigated whether Nrf2 activation affects airway inflammation and pathology induced by allergen exposure in vivo. Na€ ıve BALB/c mice were treated with CDDO-Me or DMSO (control) and exposed to Alternaria extract three times per week for 2 weeks ( Figure 6A ).
In this subchronic exposure model, the control mice developed marked airway eosinophilia and increases in IL-5 and IL-13 protein expression in lungs ( Figure 6B) ; total serum IgE levels also increased.
Alternaria-induced airway eosinophilia and enhanced expression of type-2 cytokines in lungs were significantly decreased in mice deficient in the IL-33 receptor ST2 (Fig. S6) , suggesting that IL-33 plays a key role in this model. Importantly, these allergic immune responses were nearly abolished (airway eosinophilia and IgE expression) or significantly inhibited (IL-5 and IL-13 expression, P<.05 and P<.01, respectively) in mice treated with CDDO-Me ( Figure 6B ). Histologic examination of lung tissues showed peribronchial infiltration of inflammatory cells and mucus hyperplasia in Alternaria-exposed control mice; these responses were significantly reduced in mice treated with CDDO-Me ( Figure 6C ,D, P<.05).
| DISCUSSION
The role of IL-33 in asthma and allergic diseases has been increasingly recognized. [8] [9] [10] However, little information is available regarding the regulatory mechanisms of this cytokine. A novel concept derived from this study is that airway epithelial cells develop an Reactive oxygen species are well-conserved cellular response molecules, as are ATP and calcium. A complex network of these molecules likely takes place in response to cellular stresses. 33 Furthermore, a recent study showed that allergen-induced ATP secretion activates the NADPH oxidase dual oxidase 1 (DUOX1), leading to redox-dependent activation of Src/EGFR, which mediates IL-33 processing and secretion. 24 In this study, the intracellular levels of Generally, the redox state of the healthy lung is reducing due to the abundance of antioxidant molecules available on the surface of, and within, airway epithelial cells. 37 Potential roles for imbalance in this homeostasis in the pathophysiology of asthma have been recognized. 12 In this regard, Nrf2 is likely the most important regulator of antioxidant molecules. [14] [15] [16] 28 Significant effort has been taken recently to develop pharmacologic agents that selectively activate the Nrf2 pathway. 32 Indeed, one of these agents, CDDO-Me, enhances expression of various endogenous antioxidant molecules in wild-type mice, but not in Nrf2À /À mice. 38 In this study, treatment with CDDO-Me enhanced steady-state expression of glutamatecysteine ligase (GCL), thioredoxin reductase (TXNRD), NADPH quinone dehydrogenase (NQO1), and glutathione S-transferase pi 1 (GSTP1) in mouse lungs (Fig. S4) . GCL catalyzes GSH synthesis and TXNRD catalyzes reduction of cystine to cysteine, thus promoting GSH synthesis. 28 NADPH is a reducing agent and is required for the regeneration of GSH and TXNRD. GSTP1 is a ROS-detoxifying enzyme. Therefore, these molecules likely work together to promote potent antioxidant responses in the lungs. Indeed, CDDO-Me treatment increased the steady-state BAL and lung levels of GSH by 98% and 40%, respectively (Fig. S5B) .
When used in an in vitro allergen exposure model, CDDO-Me at nanomolar concentrations prevented increases in intracellular ROS and extracellular IL-33 release ( Figure 5 ). CDDO-Me also partially inhibited IL-33 release in vivo in mice (Fig. S5B ) and significantly inhibited airway inflammation when mice were exposed repeatedly to Alternaria extract ( Figure 6 ). We acknowledge that potential offtarget effects of CDDO-Me cannot be ruled out, as with any pharmacologic agent. Indeed, while we verified activation of a number of Nrf2-target genes (Fig. S4) , the efficacy of CDDO-Me may involve other molecules that may or may not be regulated by redox, such as peroxisome proliferation-activated receptor c (PPAR c) and the nuclear factor-jB pathway. 39 Nonetheless, epithelium-specific activation of Nrf2 through a conditional Keap1 knockout strategy demonstrated cytoprotective effects of Nrf2 in mouse airways. 40 Furthermore, airway administration of exogenous GSH prevented IL-33 release and the ensuing innate type-2 immune response when mice were exposed to extracts of Alternaria (Figure 4 ). In contrast, GSH did not affect IL-33-induced production of type-2 cytokines, suggesting that it does not inhibit activation of group 2 innate lymphoid cells directly. Thus, activation of Nrf2 and production of antioxidant molecules, such as GSH, likely create a protective environment in allergen-exposed airway epithelium.
Finally, recent discoveries of epithelium-derived cytokines that mediate type-2 immune responses, such as IL-25, IL-33, and TSLP, 5 opened a new window for the treatment of patients with asthma and allergic diseases. These molecules and their receptors can be targeted directly with biologic agents such as antibodies. 4, 41 Alternatively, the pathways leading to production and secretion of these molecules can be altered by pharmacologic agents. In this regard, our findings, together with those of others, 24 suggest that oxidative stress serves as a key checkpoint by which airway epithelium initiates IL-33 release in response to allergen exposure. Furthermore, GSH levels in lung epithelial lining fluid decrease quickly after allergen exposure in humans, 42 and a lack of Nrf2 favors Th2-type immune responses in airways. 43 Therefore, activation of Nrf2 and its target antioxidant molecules may provide an excellent opportunity for regulating airway redox states and disease processes. Thus, the potential utility of Nrf2 activators for treatment of patients with asthma and related disorders must be considered as Nrf2 activators have already been examined in other medical fields. [16] [17] [18] 28, 30 Furthermore, identification of biomarkers to evaluate airway oxidative stress in patients with asthma will be necessary to identify appropriate patient populations and to evaluate treatment outcomes. 
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